Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4426-4433

  Wang, Weiguang ^a   Kumar, Pat ^a   Wang, Weizhi ^a   Epstein, John ^b   Helman, Lee ^c   Moore, Jim V ^d   Kumar, Shant ^d,e  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KINETICS; MICE; MICE, NUDE; MICROCIRCULATION; MUSCLE, SKELETAL; NEOVASCULARIZATION, PATHOLOGIC; PAIRED BOX TRANSCRIPTION FACTORS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0032189704     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Enzinger, F. M., and Weiss, S. M. Rhabdomyosarcoma. In: F.M. Enzinger and S. M. Weiss (eds). Soft Tissue Tumors, pp. 448-488. St. Louis, MO: C. V. Mosby Co., 1988.
2. Goulding, M. D., Chalepakis, G., Deutsch, U., Erselius, J. R., and Gruss, P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J., 10: 1135-1147, 1991.
3. Goulding, M. D., Lumsden, A., and Paquette, A. J. Regulation of PAX-3 expression in the dermomyotome and its role in muscle development. Development (Camb.), 120: 957-971, 1994.
4. Maroto, M., Reshef, R., Münsterberg, A. E., Koester, S., Goulding, M., and Lassar, A. B. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell, 89: 139-148, 1997.
5. Tajbakhsh, S., Rocancourt, D., Cossu, G., and Buckingham, M. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell, 89: 127-138, 1997.
6. Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Giovanni, R., and Emanuel, B. S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet., 3: 113-119, 1993.
7. Galili, N., Davis, R. J., Fredericks, W. J., Mukhopadhyay, S., Rauscher, F. J., III, Emanuel, B. S., Rovera, G., and Barr, F. G. Fusion of a forkhead domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet., 5: 30-35, 1993.
8. Shapiro, D. N., Sublett, J. E., Li, B., Downing, J. R., and Naeve, C. W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res., 53: 5108-5112, 1993.
9. Schäfer, B. W., Czerny, T., Bernasconi, M., Genini, M., and Busslinger, M. Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. Nucleic Acids Res., 22: 4574-4582, 1994.
10. Bennicelli, J. L., Fredericks, W., Wilson, R. B., Rauscher, F. J., III, and Barr, F. G. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene, 11: 119-130, 1995.
11. Bennicelli, J. L., Edwards, R. H., and Barr, F. G. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc. Natl. Acad. Sci. USA, 93: 5455-5459, 1996.
12. Fredericks, W. J., Galili, N., Mudhopadhyay, S., Rovera, G., Bennicelli, J., Barr, F. G., and Rauscher, F. J. The PAX3-FKHR fusion protein created by the T(2/13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol., 15: 1522-1535, 1995.
13. Epstein, J. A., Lam, P., Jepeal, L., Maas, R. S., and Shapiro, D. N. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J. Biol. Chem., 270: 11719-11722, 1995.
14. Sara, V. R., and Hall, K. Insulin-like growth factors and their binding proteins. Physiol. Rev., 70: 591-614, 1990.
15. Florini, J. R., and Ewton, D. Z. Highly specific inhibition of IGF-I-stimulated differentiation by an antisense oligodeoxyribonucleotide to myogenin mRNA. No effects on other actions of IGF-I. J. Biol. Chem., 265: 13435-13437, 1990.
16. Florini, J. R., Ewton, D. Z., and Coolican, S. A. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr. Rev., 17: 481-517, 1996.
17. El-Badry, O. M., Minniti, C., Kohn, E. C., Houghton, P. J., Daughaday, W. H., and Helman, L. J. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ., 1: 325-331, 1990.
18. Minniti, C. P., Tsokos, M., Newton, W. A., and Helman, L. J. Specific expression of insulin-like growth factor II in rhabdomyosarcoma tumor cells. Am. J. Clin. Pathol., 101: 198-203, 1994.
19. DeChiara, T. M., Robertson, E. J., and Efstratiadis, A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell, 64: 849-859, 1991.
20. Zhan, S. L., Shapiro, D. N., and Helman, L. J. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Investig., 94: 445-448, 1994.
21. Minniti, C. P., Luan, D., O'Grady, C., Rosenfeld, R. G., and Helman, L. J. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ., 6: 263-269, 1995.
22. Wang, W., Kumar, P., Schwarz, M., Malone, G., Haworth, A., and Kumar, S. PCR amplification of 40-year-old paraffin-embedded tumour tissues: comparison of four different DNA extraction and purification methods. Int. J. Oncol., 5: 453-457, 1994.
23. Ijiri, K., and Potten, C. S. Response of intestinal cells of differing topographical and hierarchical status to 10 cytotoxic drugs and 5 sources of radiation. Br. J. Cancer, 47: 175-185, 1983.
24. Chiou, S. T., and Chang, W. C. Insulin-like growth factor I stimulates transcription of the c-jun proto-oncogene in BALB/C 3T3 cells. Biochem. Biophys. Res. Commun., 183: 524-531, 1992.
25. Baserga, R., Porcu, P., and Sell, C. Oncogenes, growth factors and control of the cell cycle. Cancer Surv., 16: 201-213, 1993.
26. Williams, B. A., and Ordahl, C. P. Pax-3 expression in segmental mesoderm marks early stages in myogenic cell specification. Development (Camb.), 120: 785-796. 1994.
27. Sublett, J. E., Jeon, I. S., and Shapiro, D. N. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene. 11: 545-552. 1995.
28. De Klein, A., van Kessel, A. G., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., and Stephenson, J. R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature (Lond.), 300: 765-767, 1982.
29. Perkins, A., Kongsuwan, K., Visvader, J., Adams, J. M., and Cory, S. Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia. Proc. Natl. Acad. Sci. USA, 87: 8398-8402, 1990.
30. Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D., Webber, B. L., Houghton, P. J., Houghton, J. A., and Green, A. A. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet. Cell Genet., 45: 148-155, 1987.
31. Wexhe, W. A., Fletcher, C. D., Dias, P., Houghton, P. J., and Parham, D. M. Immunohistochemistry of Myo D1 in adult pleomorphic soft tissue sarcomas. Am. J. Surg. Pathol., 19: 261-269, 1995.
32. Leventhal, P. S., and Feldman, E. L. Insulin-like growth factors as regulators of cell motility-signaling mechanisms. Trends Endocrinol. Metab., 8: 1-6, 1997.
33. Bober, E., Franz, T., Arnold, H., Gruss, P., and Tremblay, P. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development (Camb.), 120: 603-612, 1994.
34. Harrington, E. A., Fanidi, A., and Evan. F. G. Oncogenes and cell death. Curr. Opin. Genet. Dev., 4: 120-129, 1994.
35. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
36. Parangi, S., O'Reilly, M. S., Christofori, G., Holmgren, I., Grosfeld, J., Folkman, J., and Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA, 93: 2002-2007, 1996.